Freeline Reports Full Year 2021 Financial Results and Business Highlights
March 31, 2022 16:01 ET
|
Freeline Therapeutics
Phase 1/2 programs on track in Hemophilia B and Gaucher disease and accelerated in Fabry disease Extended financial runway and streamlined organization support Companythrough key data readouts across...
EHang Reports Fourth Quarter and Fiscal Year 2021 Unaudited Financial Results
March 29, 2022 06:00 ET
|
EHang Holdings Limited
Annual Gross Margin Reached 63.4%Special Conditions for the EH216-S Type Certification Adopted by the CAACOperational Trial Flights under the 100 Air Mobility Routes Initiative Expanded to Over 4,000...
Freeline Announces Updated Development Plan and Timelines for FLT190 for People with Fabry Disease
March 24, 2022 07:00 ET
|
Freeline Therapeutics
Company to progress to second dose cohort in the MARVEL-1 study immediately, with first patient dosing expected in mid-2022 LONDON, March 24, 2022 (GLOBE NEWSWIRE) -- Freeline...
EHang to Report Fourth Quarter and Fiscal Year 2021 Unaudited Financial Results on Tuesday, March 29, 2022
March 22, 2022 07:59 ET
|
EHang Holdings Limited
GUANGZHOU, China, March 22, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading autonomous aerial vehicle (“AAV”) technology platform...
Freeline Announces $26.1 Million Registered Direct Offering of American Depositary Shares
March 10, 2022 21:16 ET
|
Freeline Therapeutics
LONDON, March 11, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
EHang Receives Pre-order for 60 Units of Passenger-grade AAVs from AEROTREE, Malaysia’s Leading Aviation Company, under Strategic Partnership
March 10, 2022 06:42 ET
|
EHang Holdings Limited
Strategic partnership between AEROTREE and EHang to co-develop urban air mobility business in MalaysiaThe largest pre-order for EHang’s electric passenger-grade AAVs in Malaysia that includes 50 units...
Freeline Announces First Patient Dosed in the Phase 1/2 B-LIEVE Dose-Confirmation Trial in Hemophilia B
March 09, 2022 07:44 ET
|
Freeline Therapeutics
On track to complete dosing of the first cohort and share initial data by the end of the first half of 2022 On track to start pivotal Phase 3 trial in 2023 LONDON, March 09, 2022 (GLOBE NEWSWIRE)...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, March 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on February 28, 2022, the Company granted three newly...
EHang Appoints Xin Fang as Chief Operating Officer
February 24, 2022 05:38 ET
|
EHang Holdings Limited
GUANGZHOU, China, Feb. 24, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
CAAC Formally Adopts Special Conditions for EH216-S AAV Type Certification
February 23, 2022 05:30 ET
|
EHang Holdings Limited
GUANGZHOU, China, Feb. 23, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world's leading autonomous aerial vehicle (“AAV”) technology platform company,...